INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SB
Corporate insider

Sandler Alan B.

Chief Development OfficerCIK 0001835966

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 7
Max Insider Score23
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M—
6,000 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Revolution Medicines, Inc.Chief Development Officer · Sep 18, 2026
19
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL
$244K
1,199 sh
Sep 29, 2026
Oct 1, 2026
traded Sep 29, 2026
+2d
SEC FORM 4

Evidence

19
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$62K
301 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

5
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M$353K
6,000 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

22
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$442K
2,200 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

22
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$325K
1,609 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

19
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$203K
1,000 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

23
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$67K
336 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

20
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$975
5 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence